The CRISPR-mediated Cas system is the most widely used tool in gene editing 17 and gene therapy for its convenience and efficiency. Delivery of the CRISPR system 18 by adeno-associated viruses (AAVs) is currently the most promising approach to gene 19 therapy. However, pre-existing adaptive immune responses against CRISPR nuclease 20 (PAIR-C) and AAVs has been found in human serum, indicating that immune response 21 is a problem that cannot be ignored, especially for in vivo gene correction. Non-human 22 primates (NHPs) share many genetic and physiological traits with human, and are 23 considered as the bridge for translational medicine. However, whether NHPs have same 24 PAIR-C status with human is still unknown. Here, macaques (rhesus and cynomolgus), 25 including normal housed and CRISPR-SpCas9 or TALENs edited individuals, were 26 used to detect PAIR-C which covered SaCas9, SpCas9, AsCas12a and LbCas12a. Dogs 27 and mice were also detected to expand the range of species. In addition, pre-existing 28 adaptive antibodies to AAV8 and AAV9 were performed against macaques of different 29 ages. The results showed that adaptive immunity was pre-existing in the macaques 30 regardless of Cas proteins and AAVs. These findings indicate that the pre-existing 31 adaptive immune of AAV-delivered CRISPR construction and correction system 32 should be concerned for in vivo experiments. 2 33 34 The existing popular gene editing technologies mainly include zinc finger nuclease 35 (ZFN), transcription activator-like effector nucleases (TALENs), and clustered regular 36 interspaced short palindromic repeats (CRISPR) [1-3]. Through these techniques, target 37 genes can be knocked out or knocked in, and animal models of diseases caused by gene 38 mutations can be obtained[4-7]. Due to its convenient design, simple operation and high 39 efficiency, CRISRP system has become the most used gene editing system[8]. With the 40 further development of the CRISPR system, it has begun to be applied to preclinical 41 trials to treat or repair hereditary diseases caused by gene mutations[9]. Currently, there 42 are two main methods for applying the CRISPR system to therapeutic preclinical 43 experiments. One is in vitro editing. For example, stem cells are edited in vitro, and the 44 repaired cells are returned to diseased tissues and organs[10-12]. The other is in vivo 45 editing, using vectors to deliver the CRISPR system to the diseased area by intravenous, 46 intramuscular or intraperitoneal injection[13-15]. However, due to the inherent nature 47 of the CRISPR system, its safety such as off-target[16-18], immune response[19-21] 48 and toxicity[22-24] have not been well resolved, making it a huge challenge for clinic 49 application. 50 The CRISPR system is mainly derived from bacteria and archaea [25], which often 51 invade organisms as pathogens, and are recognized as an alien by the immune system 52 of these organisms, activates lymphocytes in the body to produce corresponding 53 effector cells, and removes them[26]. It is difficult for humans or animals to avoid 54 contact with microorganisms under normal living conditions, and antibodies specific to 55 these pathogens are usually present in the body. Several research groups have found the 56 pre-existing adaptive immune responses against CRISPRCas9 nuclease (PAIR-C) are 57 extensively existing in human, which focus on specific humoral and cellular immunity 58 against SaCas9 and SpCas9[19, 20]. These findings raise concerns on the safety of the 59 in vivo CRISPR editing system. Therefore, systematic preclinical assessment of PAIR-60 C using proper laboratory animals is necessary. 61 AAVs have been widely used as a vector for gene therapy in preclinical and 62 clinical trials because it is not pathogenic. However, human and Non-human primates 63 (NHPs), as natural hosts for AAVs, have been generally found to neutralize antibodies 64 (NABs) against AAVs, which affect transduction efficiency in vivo[27, 28]. Studies 65 have shown that the capsid protein of AAVs can also be recognized by T cells, and 66 cellular immunity of AAVs cannot be ignored[29, 30]. 67 NHPs, such as macaques (rhesus and cynomolgus), are closely related to human 68 beings, have unique advantages in modeling clinic diseases, as well as preclinical safety 3 69 and efficacy assessment[31]. The pre-existing adaptive immune responses against Cas 70 proteins and AAVs assay in macaques could be helpful to promote clinical application 71 of gene editing technologies. Here, we detected the pre-existing adaptive immune 72 against AAV8 and AAV9 NABs in the serum of macaques. Meanwhile, our team 73 previously obtained several gene-editing macaque models by injecting TALENs 74 plasmid or CRISPR-Cas9 system in one-cell embryos[4, 7]. These models are quite 75 valuable for evaluate the PAIR-C in gene edited and normal wild-type monkeys. In 76 addition, adaptive antibodies against Cas9 proteins have been found in humans[20], but 77 it is not clear whether other species are the same. Organisms have been found to have 78 adaptive antibodies against type II Cas9 nucleases, while type V Cas12a (Cpf1) 79 nucleases have not been reported[20, 32]. To verify whether there are preexisting 80 antibodies against Cas proteins in macaques and other species, we designed prokaryotic 81 expression vectors to express SaCas9, SpCas9, AsCas12a (AsCpf1) and LbCas12a 82 (LbCpf1) proteins in Escherichia coli, and purified the four proteins by Ni-NTA affinity 83 chromatography column. Serum samples of macaques, dogs, and SPF mice were 84 isolated, and the pre-existing adaptive immune was assayed by western blot and ELISA. 85 Results 86 NABs against AAVs are widespread in macaques 87
Introduction 5 141 S1). Statistical results indicate that all dog serum samples were present for antibodies 142 to these four Cas proteins (Table 1, S5 Table) . Moreover, 15 of the 16 SPF mice 143 detected antibodies against these four Cas proteins (Table 1, S6 Table) . Due to the 144 exposure duration for monkeys and dogs are quite shorter than for mice, it indicated the 145 real PAIR-C levels in mice are different with dogs and monkeys. 146 147 Quantitative comparison of antibody level 148 To compare antibody levels in the same species and in different species, we further 149 adopted ELISA to quantify antibody levels in different serum samples. Since the ELISA 150 indirect method requires high-purity antigen (Cas proteins) for coating, it is difficult to 151 ensure the accuracy of the ELISA results by one-step purification of the protein by a 152 Ni-NTA affinity chromatography column [36, 37] . To meet the needs of the experiment, 153 we chose the most commonly used SpCas9 nuclease, which is also the effector of the 154 CRISPR in gene editing monkeys, and purchased the SpCas9 recombinant protein.
155 According to ELISA results, we found that antibody levels in macaques tend to increase 156 with age and remain relatively stable after adulthood (Fig 2a) . One-way analysis of 157 variance (ANOVA) of wild-type monkeys, dogs, and mice showed that there were 158 significant differences between monkeys and mice, as well as between dogs and mice.
159 But there was no significant difference between monkeys and dogs (Fig 2b) . We also 160 performed a one-way ANOVA of the macaque positive and negative groups edited by 161 CRISPR-Cas9 and TALENs, with no significant differences (Fig 2c and 2d ). At the 162 same time, the wild-type population was compared with the monkey population edited 163 by CRISPR-Cas9 and TALENs, and no significant difference was found (Fig 2e) . 
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Currently, mammalian gene editing generally serves two purposes. One is to use 203 the CRISPR system to edit the early embryo stage to obtain animal models of certain 204 diseases, and the other is to deliver CRISPR system to specific tissues and organs by 205 vectors such as AAVs to treat certain genetic diseases [8, 9] 
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